公开(公告)号：US20240189290A1

公开(公告)日：2024-06-13

申请号：US18411773

申请日：2024-01-12

Applicant: XSPRAY PHARMA AB

Inventor： Magnus BRISANDER ,  Mustafa DEMIRBÜKER ,  Gérald JESSON ,  Martin MALMSTEN ,  Helene DÉRAND

IPC: A61K31/44 ,  A61K9/00 ,  A61K9/14 ,  A61K9/16 ,  A61K9/51 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61K31/44 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/5138 ,  A61K9/5146 ,  A61K9/5161 ,  A61K9/5192 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K47/32 ,  A61K47/38

Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

公开(公告)号：US12005065B2

公开(公告)日：2024-06-11

申请号：US18307718

申请日：2023-04-26

Applicant: Spruce Biosciences, Inc.

Inventor： Alexis Howerton ,  Hal Gerber ,  Michael Huang

IPC: A61K31/5377 ,  A61K9/14 ,  A61K9/48 ,  A61K31/573 ,  A61P5/00 ,  A61P5/24 ,  A61P5/38 ,  C07D487/04

CPC classification number: A61K31/5377 ,  A61K9/14 ,  A61K9/48 ,  A61K9/4825 ,  A61K31/573 ,  A61P5/00 ,  A61P5/24 ,  A61P5/38 ,  C07D487/04 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00

Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

公开(公告)号：US12005047B2

公开(公告)日：2024-06-11

申请号：US18361837

申请日：2023-07-29

Applicant: Biohaven Therapeutics Ltd.

Inventor： Jay Edward Wrobel ,  Allen B. Reitz ,  Jeffery Claude Pelletier ,  Garry Robert Smith ,  Haiyan Bian

IPC: A61K31/428 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K38/05 ,  A61K38/06 ,  A61K39/00 ,  A61K45/06 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00 ,  C07D277/82 ,  C07D417/12 ,  C07K5/062 ,  C07K5/083 ,  C07K5/087

CPC classification number: A61K31/428 ,  A61K9/006 ,  A61K9/1617 ,  A61K9/2004 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K38/05 ,  A61K38/06 ,  A61K39/4636 ,  A61K45/06 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00 ,  C07D277/82 ,  C07D417/12 ,  C07K5/06026 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/0812 ,  A61K2300/00

Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

公开(公告)号：US20240181066A1

公开(公告)日：2024-06-06

申请号：US18472993

申请日：2023-09-22

Applicant: Nuvation Bio Inc.

Inventor： David HUNG ,  Son Minh PHAM ,  Sarvajit CHAKRAVARTY ,  Jiyun CHEN ,  Jayakanth KANKANALA ,  Jeremy D. PETTIGREW ,  Anup BARDE ,  Anjan Kumar NAYAK

IPC: A61K47/55 ,  A61K9/00 ,  A61K31/438 ,  A61K31/4745 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  A61K47/68 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D471/06

CPC classification number: A61K47/55 ,  A61K9/0053 ,  A61K31/438 ,  A61K31/4745 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  A61K47/6877 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D471/06

Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

公开(公告)号：US20240180929A1

公开(公告)日：2024-06-06

申请号：US18042648

申请日：2021-08-23

Applicant: TEXAS BIOMEDICAL RESEARCH INSTITUTE

Inventor： Larry Schlesinger ,  Eusondia Arnett

IPC: A61K31/635 ,  A61K31/4162 ,  A61K31/426 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/553 ,  A61K45/06 ,  A61P31/06

CPC classification number: A61K31/635 ,  A61K31/4162 ,  A61K31/426 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/553 ,  A61K45/06 ,  A61P31/06

Abstract: Provided are methods of treating infectious diseases by administering a BCL-2 inhibitor and a MCL-1 inhibitor to a subject in need thereof. One such infectious disease is an infection of Mycobacterium tuberculosis. Also provided are methods of inhibiting the growth of Mycobacterium tuberculosis in a granuloma by contacting the granuloma with a BCL-2 inhibitor and a MCL-1 inhibitor.

公开(公告)号：US20240180925A1

公开(公告)日：2024-06-06

申请号：US18285046

申请日：2022-03-24

Applicant: Actrevo GmbH ,  Optus Pharmaceutical Co., Ltd.

Inventor： Jens Flemming ,  Harm Peters ,  Sunghak Choi ,  Kangok Lee ,  Jinsook Ko ,  Youngwoon Park

IPC: A61K31/5575 ,  A61K9/00 ,  A61K9/08 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/10 ,  A61K47/34

CPC classification number: A61K31/5575 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/10 ,  A61K47/34

Abstract: The present invention refers to an aqueous ophthalmic composition comprising latanoprost in an amount of 0.003 weight-% to 0.007 weight-%, macrogolglycerol hydroxystearate 40 in an amount of 0.3 weight-% to 0.7 weight-%, and propylene glycol in an amount of 0.05 weight-% to 0.09 weight-%, wherein the composition is free of preservatives and stabilizing agents. Furthermore, the present invention refers to the use in the treatment of ocular hypertension and/or glaucoma.

公开(公告)号：US20240180918A1

公开(公告)日：2024-06-06

申请号：US18486783

申请日：2023-10-13

Applicant: VORONOI CO., LTD.

Inventor： Soo Chan KIM ,  Dae Kwon KIM ,  Dong Hyuk SEO ,  Hyun Kyung KIM ,  Sung Hwan KIM ,  Hye Min HWANG ,  Ji Eun CHOI

IPC: A61K31/5377 ,  A61K45/06 ,  A61P1/00 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02

CPC classification number: A61K31/5377 ,  A61K45/06 ,  A61P1/00 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02

Abstract: The present invention relates to a pharmaceutical composition for preventing and/or treating inflammatory disease, the composition comprising a pyrrolopyridine-derivative compound as an active ingredient; the compound represented by Chemical Formula 1 according to the present invention, enantiomers thereof or pharmaceutically acceptable salts thereof, which have excellent inhibitory activity against not only protein kinases but also inflammatory factors and inflammatory cytokines; therefore a pharmaceutical composition comprising the same as an active ingredient may be useful in prevention, treatment and/or improvement of inflammatory disease, in particular but not limited to inflammatory bowel disease, rheumatoid arthritis, or lupus.

公开(公告)号：US20240180851A1

公开(公告)日：2024-06-06

申请号：US18456178

申请日：2023-08-25

Applicant: Neuromagen Pharma Ltd

Inventor： Esther Priel

IPC: A61K31/09 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/66 ,  A61P15/08

CPC classification number: A61K31/09 ,  A61K31/137 ,  A61K31/4025 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/66 ,  A61P15/08

Abstract: The present invention is directed to methods and uses of a series of compounds and compositions comprising the same for treating diseases, disorders and/or conditions related to fertility and preserving same and conditions related to same. In some aspects, the compounds and or compositions as herein described promote, improve, recover or restore fertility in a subject in need thereof, including in male and/or female subjects. Such methods/uses include promoting, enhancing or improving fertility-associated cell or tissue yield as part of an in vitro fertilization protocol.

公开(公告)号：US11998545B2

公开(公告)日：2024-06-04

申请号：US18342314

申请日：2023-06-27

Applicant: Array BioPharma, Inc.

Inventor： Steven W. Andrews ,  Sean Aronow ,  James F. Blake ,  Barbara J. Brandhuber ,  Adam Cook ,  Julia Haas ,  Yutong Jiang ,  Gabrielle R. Kolakowski ,  Elizabeth A. McFaddin ,  Megan L. McKenney ,  Oren T. McNulty ,  Andrew T. Metcalf ,  David A. Moreno ,  Tony P. Tang ,  Li Ren

IPC: C07D401/02 ,  A61K31/437 ,  A61K31/444 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  A61P1/12 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07D401/10 ,  C07D471/04 ,  C07D519/00

CPC classification number: A61K31/496 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  A61P1/12 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07D471/04 ,  C07D519/00

Abstract: Provided herein are compounds of the Formula I:




and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20240173432A1

公开(公告)日：2024-05-30

申请号：US18456288

申请日：2023-08-25

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Guoxiang Ruan ,  Jianming Liu ,  Tudor Fulga ,  Mehmet Fatih Bolukbasi ,  Eric Gunnar Anderson ,  Lingjun Rao ,  Norzehan Abdul-Manan ,  Matthias Heidenreich ,  Gregoriy Aleksandrovich Dokshin ,  Jesper Gromada

IPC: A61K48/00 ,  A61K31/506 ,  A61K31/5377 ,  A61P19/00 ,  C12N9/22 ,  C12N15/11

CPC classification number: A61K48/005 ,  A61K31/506 ,  A61K31/5377 ,  A61P19/00 ,  C12N9/22 ,  C12N15/11 ,  C12N2310/20

Abstract: Compositions and methods for treating Myotonic Dystrophy Type 1 (DM1) are encompassed.